以岭药业：盐酸美金刚化学原料药上市申请获批准，治疗中重度至重度阿尔茨海默型痴呆

Core Viewpoint - Yiling Pharmaceutical (002603) announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd., has received the approval notice for the listing application of Memantine Hydrochloride from the National Medical Products Administration [1] Group 1: Company Developments - Wanyang Hengshui submitted the listing application for Memantine Hydrochloride, which has now been approved [1] - Memantine Hydrochloride is a voltage-dependent, moderate-affinity, non-competitive NMDA receptor antagonist [1] - The drug is indicated for the treatment of moderate to severe Alzheimer's disease by blocking pathological increases in glutamate concentration that lead to neuronal damage [1]